Mankind Pharma reported a 17% year-on-year decline in net profit for the first quarter, even as revenue edged upward, reflecting a complex interplay between rising input costs and strategic expansion initiatives. While the company managed to increase its total income from operations, profit margins came under pressure due to elevated raw material costs, marketing spend, and international business scaling. Despite the dip in quarterly earnings, Mankind Pharma remains optimistic about long-term prospects, driven by a broad portfolio in domestic and export markets.